Overview
Helena Gopar-Reyes practices practicing medicine in Mexico City, Mexico.
Her clinical expertise encompasses Burkitt Lymphoma, Triple-Negative Breast Cancer, and Follicular Lymphoma.
She is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Helena Gopar-Reyes
Is Helena Gopar-Reyes a top-rated expert for Burkitt Lymphoma?
MediFind is an objective health platform that identifies experts based on real-world data. Helena Gopar-Reyes is classified as an Experienced expert for Burkitt Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Helena Gopar-Reyes participate in research or clinical trials?
Yes. Helena Gopar-Reyes has published 11 articles and abstracts on conditions like Burkitt Lymphoma. You can view a list of Helena Gopar-Reyes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Burkitt LymphomaMs. Gopar-Reyes isExperienced. Learn about Burkitt Lymphoma.
- Follicular LymphomaMs. Gopar-Reyes isExperienced. Learn about Follicular Lymphoma.
- Triple-Negative Breast CancerMs. Gopar-Reyes isExperienced. Learn about Triple-Negative Breast Cancer.